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Heparin is a highly sulfated polysaccharide that
regulates a variety of cellular processes by inter-
action with a host of proteins. We report the
preparation of synthetic heparin oligosaccha-
ride glycodendrimers and their use as heparin
mimetics to regulate heparin-protein interac-
tions. The multivalent display of sugar epitopes
mimics the naturally occurring glycans found on
cell surfaces and enhances their binding capac-
ity. Binding of the heparin dendrimers to basic fi-
broblast growth factor (FGF-2) was analyzed us-
ing heparin microarray experiments and surface
plasmon resonance measurements on gold
chips. Heparin-coated dendrimers bind FGF-2
significantly more effectively than monovalent
heparin oligosaccharides. Dendrimer 1, which
displays multiple copies of the sulfated hexa-
saccharide (GlcNSO3[6-OSO3]-IdoA[2-OSO3])3,
was employed to promote FGF-2-mediated
mitogen-activated kinase activation, demon-
strating the utility of glycodendrimers to modu-
late heparin-protein interactions.
INTRODUCTION
Heparin, a highly sulfated and heterogeneous polysaccha-
ride, has been the drug of choice in the prevention and
treatment of thromboembolic disorders for nearly 70 years
[1]. In addition to their antithrombic activity, heparin and
the structurally related heparan sulfate are involved in
a wide variety of biological processes by interaction with
a host of proteins [2–9]. For instance, heparan sulfate
present on cell surfaces plays a key role in leukocyte entry
into sites of inflammation by interaction with P- and L-
selectins and proinflammatory chemokines [10, 11]. The
interaction of heparin with growth factors, such as FGF-
2, modulates cell proliferation and angiogenesis [12–14].
Consequently, heparin analogs as therapeutic substitutes
of the natural product, with a similar or even better phar-Chemistry & Biology 14, 87macological profile but lacking the disadvantages of
heparin, are of considerable interest. The natural biopoly-
mer holds the potential risk of pathogen contamination
because it is isolated from mammalian sources. Undesir-
able, severe side effects associated with heparin include
heparin-induced thrombocytopenia and bleeding [15].
Dendrimers are hyperbranched synthetic macromole-
cules of defined structure and molecular weight that
have been evaluated for biomedical applications [16].
Placement of terminal sugar residues on dendrimers cre-
ates a multivalent display that mimics cell-surface glycans
[17–19]. Multivalent presentation of sugar epitopes on an
appropriate macromolecular scaffold increases binding
due to the cluster effect and improves carbohydrate-
protein interactions [20–23].
Recently, we prepared amine-functionalized heparin
oligosaccharides for immobilization on glass slides to pro-
duce heparin chips [24–28]. This amine terminus allows for
the attachment to dendrimers to create heparin function-
alized conjugates of well-defined structure. Anionic den-
drimers containing D-glucosamine and D-glucosamine
6-sulfate prevent scar tissue formation after glaucoma fil-
tration surgery in a rabbit model [29]. Dendrimers with cat-
ionic end groups are often toxic [29]. Therefore, we de-
cided to use anionic, polyamidoamine (PAMAM)
dendrimers to prepare multivalent conjugates of synthetic
heparin oligosaccharides. Dendrimer binding to FGF-2
was analyzed using heparin microarrays and surface plas-
mon resonance (SPR) measurements on gold chips. Hep-
arin-coated dendrimers bind FGF-2 significantly better
than monovalent heparin oligosaccharides. Dendrimer 1
(Figure 1), which displays several copies of the sulfated
hexasaccharide 6, promotes FGF-2-mediated activation
of mitogen-activated kinase signaling. Therefore, heparin
dendrimers may potentially constitute novel therapeutic
agents for tissue repair and regeneration.
RESULTS AND DISCUSSION
Preparation of Synthetic Heparin Oligosaccharide
Glycodendrimers
Four different synthetic heparin sequences (6–9) contain-
ing an amine group linked to the reducing ends were used9–887, August 2007 ª2007 Elsevier Ltd All rights reserved 879
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Heparin Oligosaccharide DendrimersFigure 1. Structure of Polyvalent Dendrimer Conjugates 1–5 and Heparin Oligosaccharides 6–9to construct heparin glycodendrimers 1–4 (Figure 1). Dis-
ulfated monosaccharide 9 served as a model to optimize
the coupling chemistry. Generation 2.5 PAMAM den-
drimer 5, which contains 32 carboxylic acid groups, was
activated with N-ethyl-N0-(dimethylaminopropyl) carbodii-
mide (EDC) and N-hydroxysuccinimide (NHS) in DMSO.
Coupling with 9 in the presence of triethylamine gave, after
purification by centrifugal ultrafiltration, the desired glyco-
dendrimer 4. Sugar conjugation was estimated by 1H
NMR in D2O. Comparison of the signals of sugar protons
and protons for the dendritic core indicated that approxi-
mately eight sugar residues on each dendrimer were pres-
ent (25% loading) (Experimental Procedures; see the
Supplemental Data available with this article online). At-
tempts to increase sugar loading by varying reaction
time and EDC, NHS, and ligand per carboxylic acid con-
centrations did not improve conjugation. The steric hin-
drance or electrostatic repulsion between the anionic den-
drimer and the sulfate sugar groups likely prevents higher
substitution. Multivalent display and accessibility of sugar
epitopes for protein recognition should be suitable at 25%
loading. Following this protocol, glycodendrimers 1, 2,
and 3 were obtained by coupling the PAMAM dendritic
core and oligosaccharides 6–8.
Competition Experiments on Heparin Microarrays
to Estimate Binding Affinities of Glycodendrimers
and FGF-2
FGF-2 is a prototypical member of the fibroblast growth
factor (FGF) family and participates in a variety of biologi-
cal processes including cell proliferation, cell differentia-
tion, and angiogenesis [12, 30]. The heparin binding profile
of FGF-2 was recently determined using heparin microar-880 Chemistry & Biology 14, 879–887, August 2007 ª2007 Elserays [24, 27]. FGF-2 strongly binds hexasaccharide 6.
Disaccharide 7 and monosaccharide 8 are bound less
tightly, whereas 9 is not bound at all.
Binding affinities of dendrimers 1–3 and FGF-2 were an-
alyzed by determining IC50 values [31] of soluble den-
drimers with heparin-coated microarrays. The monovalent
sugars 6–9 were also employed in these experiments. IC50
values were defined as concentrations of soluble compet-
itor that inhibit 50% of FGF-2 binding to immobilized
heparin. CodeLink glass slides were subdivided into eight
different sections using an eight-well hybridization cham-
ber [32]. A deaminated heparin sample (5 kDa) was func-
tionalized with 1,11-diamino-3,6,9-trioxaundecane by
reductive amination and printed in each well. Thus, eight
different binding experiments can be performed on each
slide (Figure 2). A series of FGF-2 (29 nM) mixtures with
competitors (0.5 nM to 500 mM) was incubated on the ar-
rays. A solution of FGF-2 without competitor served as
control. Preincubation of the protein solution with the
competitor for 1 hr prior to hybridization on the glass slide
did not influence the results. Bound FGF-2 was detected
by incubation with rabbit anti-FGF-2 polyclonal antibody
followed by hybridization with fluorescently labeled anti-
rabbit secondary antibody [24, 27].
Dendrimer 1 (IC50 = 1.4 mM; log IC50 = 5.86 ± 0.13)
competed more effectively with immobilized heparin
than monovalent heparin oligosaccharide 6 (Figure 3).
Similarly, IC50 values for 2 (43 mM; log IC50 = 4.37 ±
0.19) and 3 (165 mM; log IC50 = 3.78 ± 0.13) were deter-
mined. However, even when using high concentrations of
monovalent 7 and 8 (2.5 mM), only negligible inhibition
was observed. These observations indicate that den-
drimers 2 and 3 are significantly better ligands for FGF-2vier Ltd All rights reserved
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Heparin Oligosaccharide DendrimersFigure 2. Eight-Well Array for Competi-
tion Assays
Amine-functionalized heparin (5 kDa) was
printed in each well at two different concentra-
tions (0.5 mM and 1 mM, from top to bottom), in
17 replicates. The wells were incubated with
mixtures of FGF-2 and competitor (5 kDa hep-
arin in this figure) and the bound protein was
detected by antibody staining using rabbit
anti-FGF-2 polyclonal and Alexa Fluor 546-
labeled anti-rabbit antibodies. This microarray
competition experiment allowed for the esti-
mation of binding affinities of compounds 1–9.than oligosaccharides 7 and 8. Still, both glycodendrimers
2 and 3 displayed weaker binding than 1. Soluble heparin
(5 kDa) served as positive control in these competition as-
says. The IC50 value of soluble heparin (28 nM; log IC50 =
7.55 ± 0.15) is in good accordance with reported data
using an optical biosensor and 12.5 kDa heparin [33]
(Supplemental Data). Simple nonspecific charge-charge
interactions can be ruled out because 4, 5, and 9 failed
to inhibit FGF-heparin binding, even at high concentra-Chemistry & Biology 14, 87tions (Supplemental Data). These results are in agreement
with the carbohydrate binding profile of FGF-2 [24, 27] and
suggest that the multivalent presentation of heparin oligo-
saccharides on an appropriate macromolecular scaffold
amplifies their affinity for heparin-binding proteins.
SPR Experiments to Determine Binding Affinities
The binding results obtained with heparin microarrays
were validated by SPR experiments. The characterizationFigure 3. Binding Affinities Using Microarray Experiments
Determination of concentrations of soluble glycodendrimers 1 (A), 2 (B), and 3 (C) to inhibit 50% of FGF-2 binding to immobilized heparin on the car-
bohydrate microarray (IC50 values) and ability of monovalent 6 (D), 7 (E), and 8 (F) to compete with immobilized heparin in FGF-2 binding. For the
dendrimers, the concentration is moles of oligosaccharide. Data presented are the average of 17 spots on the same array; errors are the standard
deviations for each measurement.9–887, August 2007 ª2007 Elsevier Ltd All rights reserved 881
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Heparin Oligosaccharide DendrimersFigure 4. Binding Affinities Using SPR Measurements
SPR curves showing the real-time binding of a series of mixtures of FGF-2 (25 nM) and compounds 1 (A), 2 (B), 3 (C), 6 (D), 7 (E), and 8 (F) (5 nM to
500 mM) to a sensor chip presenting hexasaccharide 6. For the dendrimers, the concentration is moles of oligosaccharide. RU, response units.of dendrimer-FGF-2 interactions using an optical biosen-
sor rules out any artifact caused by primary and secondary
antibody staining. Moreover, SPR provides additional in-
formation on heparin-protein interactions in real time
[34]. Inhibition of FGF-2 binding to heparin-like surfaces
by heparin dendrimers was measured using a gold chip
carrying immobilized 6.
Biotinylated heparin or heparan sulfate is usually immo-
bilized on a streptavidin-coated sensor chip [35–38].
Synthetic, amine-functionalized heparin oligosaccharides
were directly immobilized on the gold surfaces. Hexasac-
charide 6 was coupled to an activated CM5 gold chip by
using a 1 mM solution of hexadecyltrimethylammonium
chloride. The covalent amide bond formation on CM5
chips is favored in a low-ionic strength buffer at a pH be-
low the isoelectric point of the molecule that is immobi-
lized [39]. The ligand is concentrated on the chip surface
by electrostatic attraction between the positively charged
ligand and the negatively charged carboxyl groups of the
chip. Immobilization of highly sulfated heparin oligosac-
charides (e.g., 6) by amine coupling is difficult, as the pres-
ence of negatively charged sulfate groups prevents elec-
trostatic preconcentration. Using positively charged
micelles as ligand carriers overcomes this problem.
FGF-2 solutions (25 nM) containing increasing concen-
trations of dendrimers or sugars (from 0.5 nM to 500 mM)
were flowed over the gold chip and the SPR sensorgrams
were recorded (Figure 4). Positive (5 kDa heparin) and
negative (5) controls were also measured (Supplemental882 Chemistry & Biology 14, 879–887, August 2007 ª2007 ElseData). Binding of FGF-2 to immobilized hexasaccharide
6 was not significantly inhibited by 4, or by the anti-ulcer
drug sucrose octasulfate, which has been shown to bind
to FGF [40] (Supplemental Data). As little as 500 nM 1 de-
creased the SPR response to 37%, whereas 500 mM
monovalent 6 was required to produce a similar decrease
of the signal (Figure 4). These results demonstrate the im-
portance of multivalent presentation of heparin epitopes
for enhancing protein binding, by mimicking the naturally
occurring heparin-like oligosaccharides found on cell-
surface proteoglycans.
FGF-2 Activity Assay
We determined the capacity of dendrimer 1 to influence
the effect of FGF-2 on the activation of the mitogen-
activated kinase signaling pathway. Phosphorylation of
extracellular signal-regulated kinases 1 and 2 (ERK1/2)
in response to FGF was monitored for this purpose. Fibro-
blast growth factor receptor 1-IIIc (FGFR1-IIIc)-transfected
L6 rat skeletal muscle myoblasts [41] were starved for
24 hr without supplements in the medium until they
reached quiescence and only weak bands of phosphory-
lated ERK1/2 (P-ERK1/2) were detected by western blot
analysis. Then, the cells were treated with medium without
FGF-2 or stimulated with FGF-2 (5 ng/ml) for 10 min
(Figure 5). Different concentrations of dendrimer 1, PAMAM
dendrimer 5, or hexasaccharide 6 (ranging from 50 nM to
5 mM) were incubated for 1 hr at room temperature with
FGF-2 (5 ng/ml), and the cells were then incubated forvier Ltd All rights reserved
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Heparin Oligosaccharide Dendrimers10 min with these mixtures. Similar results were obtained
without preincubation (data not shown). The cells were
harvested and lysed, and the lysates were analyzed by
western blotting with antibodies against P-ERK1/2, total
ERK1/2, and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). Dendrimer 1 without FGF-2 was not able
to activate ERK1/2 phosphorylation. The low concentra-
tion of FGF-2 we used caused only a minor increase
in ERK1/2 phosphorylation under our experimental condi-
tions (Figure 5 and data not shown). However, when cells
were treated with a mixture containing FGF-2 and den-
drimer 1, a significant increase in the P-ERK1/2 signal
was detected compared to FGF-2 alone (Figure 5). As little
as 50 nM 1 was sufficient to enhance activation, suggest-
ing that 1 is a strong stimulator of FGF-2 signaling. Non-
functionalized dendrimer 5 and hexasaccharide 6 did
not affect ERK1/2 phosphorylation in the presence or ab-
sence of FGF-2. Heparin (15 U/ml) strongly potentiated
the effect of FGF-2 under the same conditions (data not
shown).
FGF signaling involves binding to specific cell-surface
tyrosine kinase receptors (FGFRs) and is tightly regulated
by heparin-like glycosaminoglycans (HLGAGs) that facili-
tate the formation of FGF-FGFR complexes [42–44]. The
various FGFs require HLGAGs for biological activity, pre-
sumably to generate and stabilize ternary signaling com-
plexes with FGFRs. High-resolution X-ray crystal struc-
tures of FGF-FGFR-heparin complexes [45–47] have
Figure 5. FGF-2 Activity Assay
L6 rat skeletal muscle myoblasts stably transfected with an FGFR1-IIIc
expression vector were rendered quiescent and subsequently treated
with medium without FGF-2 (FGF2) or with FGF-2 (+FGF2) (5 ng/ml)
for 10 min. Different concentrations of 1, 5, or 6 were incubated for 1 hr
at room temperature with FGF-2, and cells were then incubated for
10 min with these mixtures. Treated and untreated cells were analyzed
by western blotting with antibodies against phospho-ERK1/2, total
ERK1/2, and GAPDH. The concentrations of 1, 5, or 6 are indicated
at the top of each lane. Concentration of 1 is moles of heparin oligosac-
charide.Chemistry & Biology 14, 87provided insights into structural aspects of these interac-
tions and demonstrated the complexity of the molecular
mechanism involved in heparin-mediated FGF signaling.
The results of this kinase assay suggest that 1, display-
ing multiple copies of a hexasaccharide containing the
trisulfated repeating unit of the major region of heparin,
is able to promote the formation of FGF-FGFR complexes
and activate FGF-2-mediated signaling. In addition, com-
parison of ERK1/2 phosphorylation by FGF-2 with or with-
out 1 indicates that the hexasaccharide-coated dendrimer
generates the ternary complex more efficiently than hep-
aran-sulfate chains on the surface of myoblasts. The stim-
ulation of kinase production by 1 is similar to that with
soluble heparin. Interestingly, hexasaccharide 6 did not
stimulate ERK1/2 phosphorylation. This finding empha-
sizes the importance of multivalent display to activate
FGF-2 signaling and is in agreement with reports showing
that longer heparin sequences are required for FGF acti-
vation and mitogenesis [13, 14, 48, 49].
SIGNIFICANCE
Synthetic, amine-functionalized heparin oligosaccha-
rides can be attached to hyperbranched macromole-
cules, such as dendrimers, to create novel heparin
conjugates for applications in glycobiology. We dem-
onstrate that the multivalent presentation of heparin
epitopes on the surface of PAMAM dendrimers am-
plifies the binding affinity of heparin oligosaccharides
to heparin-binding proteins such as FGF-2 drastically.
Carbohydrate microarray and SPR experiments re-
quire only miniscule amounts of dendrimer and pro-
tein to determine binding affinities. Well-defined hep-
arin dendrimers function as heparin mimetics to target
heparin-mediated biological processes. To highlight
this potential, we demonstrate that FGF-2 mitogenic
signaling in L6 myoblasts can be activated by heparin
dendrimers. These synthetic analogs may avoid the
side effects associated with natural heparin.
FGFs are potent regulators of cell proliferation and
survival, and a recombinant form of human keratino-
cyte growth factor (FGF-7) is already on the market
for the treatment of severe oral mucositis [50]. Heparin
dendrimers may provide an opportunity to discover
novel therapeutic agents for tissue repair, regenera-
tion, and cytoprotection [51, 52] by modulating hepa-
rin-FGF interactions. Blocking interactions between
heparan sulfate and different protein families, such
as selectins and chemokines that play a key role in
inflammatory processes, may be another area of den-
drimer application. New anti-inflammatory drugs with
minimal side effects may be based on synthetic hepa-
rin dendrimers.
EXPERIMENTAL PROCEDURES
General Methods
All chemicals used were reagent grade and used as supplied. All aque-
ous solutions were made from nanopure water. Starburst PAMAM9–887, August 2007 ª2007 Elsevier Ltd All rights reserved 883
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Heparin Oligosaccharide Dendrimersdendrimer generation 2.5 containing 32 sodium carboxylate surface
groups was purchased from Sigma-Aldrich (St. Louis, MO, USA). 1H-
NMR spectra were recorded on a Varian VXR-300 (300 MHz) or Bruker
ARX300 (300 MHz) spectrometer. Microcon centrifugal filter units were
purchased from Millipore (Billerica, MA, USA). Solutions used for chip
hybridizations were sterile filtered through a 0.2 mm syringe filter prior
to use. Deaminated heparin (5 kDa) was purchased from Sigma-
Aldrich. Recombinant human basic fibroblast growth factor (FGF-2)
and rabbit polyclonal anti-human FGF-2 were purchased from Pepro-
Tech EC (London, UK). Goat anti-rabbit IgG labeled with Alexa Fluor
546 dye was purchased from Invitrogen (Carlsbad, CA, USA). Code-
Link slides were purchased from Amersham Biosciences. Microarrays
were constructed using a sciFLEXARRAYER noncontact printer from
Scienion AG (Berlin, Germany). HybriSlip hybridization covers were
purchased from Grace BioLabs (Bend, OR, USA). Slides were scanned
using an LS400 scanner from Tecan (Ma¨nnedorf, Switzerland) and
quantified using Gene Spotter (MicroDiscovery GmbH, Berlin, Germany)
software. SPR measurements were performed on a BIAcore 3000
(BIAcore, Uppsala, Sweden) operated by BIAcore control software.
HBS-EP buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA,
0.005% v/v surfactant P20) and CM5 chips were purchased from
BIAcore.
Preparation of Glycodendrimers 1–4
Activation of PAMAM Dendrimer Carboxylate Groups
Commercially available methanolic PAMAM solution was concen-
trated and coevaporated with CH2Cl2 twice under reduce pressure.
The residue (20 mg, 3.2 mmol) was dissolved in anhydrous DMSO
(2 ml). EDC (23.6 mg, 122 mmol, 1.2 equivalents per carboxylate group)
and NHS (14.2 mg, 122 mmol, 1.2 equivalents per carboxylate group)
were added and the reaction mixture was stirred under an argon
atmosphere for 24 hr.
Dendrimer 4. Et3N (10 ml) and monosaccharide 9 (3.0 mg, 5.6 mmol,
1.1 equivalents per carboxylate group) were added to an aliquot of the
activated PAMAM solution (100 ml, 0.16 mmol). More DMSO (100 ml)
was then added to aid in solubility of the sugar. The reaction mixture
was stirred under argon for 24 hr and then lyophilized to remove the
DMSO. The residue was dissolved in water and purified by centrifugal
ultrafiltration (Microcon 3 kDa, 40 min, 14,000 rpm), washing twice with
water. Lyophilization in water afforded the corresponding dendrimer
4 as a white powder (1.4 mg). Some batches were submitted to an
additional purification step through Sephadex G-25 (prepacked PD-
10 column; Amersham Biosciences) in order to remove the glycerin
which coats Microcon ultrafiltration membranes and eventually con-
taminates the dendrimer sample. The ratio of sugar to dendrimer
was 8.6 (27% loading of monosaccharide 9 on the dendrimer) based
on the 1H-NMR spectrum in D2O (300 MHz) (Supplemental Data).
The molecular weight of 4 (10.5 kDa) was estimated based on NMR
integration. To estimate the molecular weights, it was assumed that
all the sulfate groups of the sugar and the carboxylic acid groups of
the dendrimer were present as sodium salts.
Dendrimer 3. Et3N (10 ml) and monosaccharide 8 (3.2 mg, 5.6 mmol,
1.1 equivalents per carboxylate group) were added to an aliquot of the
activated PAMAM solution (100 ml, 0.16 mmol). More DMSO (100 ml)
was then added to aid in solubility of the sugar. The reaction mixture
was stirred under argon for 24 hr and then lyophilized to remove the
DMSO. The residue was dissolved in water and purified by centrifugal
ultrafiltration (Microcon 3 kDa, 40 min, 14,000 rpm), washing twice with
water. Lyophilization in water afforded the corresponding dendrimer
3 as a white powder (1.6 mg). The ratio of sugar to dendrimer was 7.6
(24% loading of monosaccharide 8 on the dendrimer) based on the
1H-NMR spectrum in D2O (300 MHz) (Supplemental Data). The molec-
ular weight of 3 (10.3 kDa) was estimated based on NMR integration.
Dendrimer 2. Et3N (10 ml) and disaccharide 7 (4.7 mg, 5.6 mmol, 1.1
equivalents per carboxylate group) were added to an aliquot of the ac-
tivated PAMAM solution (100 ml, 0.16 mmol). More DMSO (100 ml) was
then added to aid in solubility of the sugar. The reaction mixture was
stirred under argon for 24 hr and then lyophilized to remove the884 Chemistry & Biology 14, 879–887, August 2007 ª2007 ElseDMSO. The residue was dissolved in water and purified by centrifugal
ultrafiltration (Microcon 3 kDa, 40 min, 14,000 rpm), washing twice with
water. Lyophilization in water afforded the corresponding dendrimer 2
as a white powder (2 mg). The ratio of sugar to dendrimer was 7.3 (23%
loading of disaccharide 7 on the dendrimer) based on the 1H-NMR
spectrum in D2O (300 MHz) (Supplemental Data). The molecular
weight of 2 (12.1 kDa) was estimated based on NMR integration.
Dendrimer 1. Et3N (10 ml) and hexasaccharide 6 (6.1 mg, 2.8 mmol,
1.1 equivalents per carboxylate group) were added to an aliquot of the
activated PAMAM solution (50 ml, 0.08 mmol). More DMSO (100 ml) was
then added to aid in solubility of the sugar. The reaction mixture was
stirred under argon for 24 hr and then lyophilized to remove the
DMSO. The residue was dissolved in water and purified by centrifugal
ultrafiltration (Microcon 10 kDa, 30 min, 14,000 rpm), washing twice
with water. Lyophilization in water afforded the corresponding den-
drimer 1 as a white powder (1.8 mg). The ratio of sugar to dendrimer
was 8.7 (27% loading of hexasaccharide 6 on the dendrimer) based
on the 1H-NMR spectrum in D2O (300 MHz) (Supplemental Data).
The molecular weight of 1 (24.9 kDa) was estimated based on NMR
integration.
Carbohydrate Microarray Experiments
Preparation of Amine-Functionalized 5 kDa Heparin
Deaminated 5 kDa heparin (2 mg, 0.4 mmol) was dissolved in MES
buffer (0.4 ml, 50 mM [pH 6.8]). 1,11-diamino-3,6,9-trioxaundecane
[53] (0.8 mg, 4 mmol) in DMF (25 ml) and NaCNBH3 (50 ml of a 0.16 M
solution in water) were added and the reaction mixture was shaken
at room temperature for 18 hr. To remove linker excess, the solution
was submitted to centrifugal ultrafiltration (Microcon 3 kDa, 40 min,
14,000 rpm), washing three times with water. The residue was diluted
with water and lyophilized to give a white solid (2 mg) that was stored
at 20C until use.
Heparin Array Fabrication
Amine-functionalized heparin (average molecular weight 5 kDa) was
dissolved in sodium phosphate buffer (50 mM [pH 9.0]) and spatially
arrayed onto N-hydroxysuccinimide (NHS)-activated CodeLink slides
by use of an automated arraying robot. Each glass slide was subdi-
vided into eight different sections and heparin was printed in each sec-
tion, at two concentrations (0.5 and 1 mM) in 17 replicates, in order to
examine eight different conditions on each slide using an eight-well
hybridization chamber. Slides were printed in 50% relative humidity
at 22C, followed by incubation overnight in a saturated NaCl chamber
that provides a 75% relative humidity environment. The robot delivered
1 nl (approximately) of heparin solution and the resulting spots had an
average diameter of 200 mm with a distance of 500 mm between the
centers of adjacent spots. Slides were then washed three times with
water to remove the unbound carbohydrates from the surface.
Remaining succinimidyl groups were quenched by placing slides in
a solution preheated to 50C that contained 100 mM ethanolamine
in sodium phosphate buffer (50 mM [pH 9.0]) for 1 hr. Slides were
rinsed several times with distilled water, dried by centrifugation, and
stored in a dessicator prior to use.
Binding Assay
As described above, heparin was spotted in eight predetermined
places on the glass slide. After attaching an eight-well hybridization
chamber to the slide, each block was incubated with 40 ml of a mixture
of FGF-2 (29 nM) and a competitor in PBS buffer (10 mM [pH 7.5]) con-
taining BSA (1%) for 1 hr at room temperature. Glycodendrimers 1–4,
PAMAM dendrimer 5, oligosaccharides 6–9, sucrose octasulfate, and
deaminated 5 kDa heparin were added as competitors at concentra-
tions ranging from 0.5 nM to 2.5 mM (Figure 3; Supplemental Data).
A solution of FGF-2 (29 nM) without competitor was used as positive
control. The arrays were washed twice with PBS (10 mM [pH 7.5])
containing 1% Tween 20 and 0.1% BSA, twice with water, and then
centrifuged for 3 min to ensure dryness. For detection of bound
FGF-2, arrays were incubated with polyclonal rabbit anti-human
FGF-2 (20 mg/ml) and then washed as above. The array incubation
was performed as follows: 100 ml of antibody solution was placedvier Ltd All rights reserved
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room temperature. Finally, Alexa Fluor 546-labeled anti-rabbit IgG
(20 mg/ml) was used to detect bound rabbit primary antibodies, and
washed as above. All the competition assays were carried out at least
in duplicate.
Image Acquisition and Signal Processing
Heparin arrays were scanned by using an LS400 scanner, and fluores-
cence intensities from these scans were integrated on Gene Spotter
software. Signal to background was typically R50:1. The local back-
ground was subtracted from the hybridization signal of each separate
spot and the mean intensity of each spot was used for data analysis.
Spot finding was automatically performed, followed by manual fitting
to correct spot deviations. Data presented are the average of 17 spots
on the same array at 1 mM; errors are the standard deviations for each
measurement. Similar results were obtained by measuring heparin mi-
crospots at 0.5 mM (data not shown).
Data Analysis
Curve fitting and calculation of IC50 values were performed with the
GraphPad Prism program (GraphPad Software, San Diego, CA,
USA). The fluorescence intensity was represented as a function of
the logarithm of concentration of competitor. The data were fitted to
a sigmoidal dose-response curve with a constant slope: Y = Bottom +
[(Top-Bottom)/(1 + 10logIC50
X)], where X is the logarithm of competitor
concentration and Y represents the fluorescence intensity (response)
that starts at Top and goes to Bottom with a sigmoid shape. For the
dendrimers, the concentration is moles of oligosaccharide.
SPR Measurements
Immobilization of Hexasaccharide 6 on a CM5 Sensor Chip
Hexasaccharide 6 was covalently bound to the sensor surface via
the primary amino group using the following protocol: HBS-EP was
employed as running buffer. The carboxymethylated dextran matrix
(CM5 chip) was first activated at a flow rate of 5 ml/min by using a
15 min (75 ml) injection pulse of an aqueous solution containing N-
hydroxysuccinimide (NHS, 0.05 M) and N-ethyl-N0-(dimethylamino-
propyl) carbodiimide (EDC, 0.2 M). Next, a 50 ml injection of 6
(500 mg/ml) in 5 mM sodium phosphate buffer (pH 7.4) containing
NaCl (1 M) was flowed over the activated surface followed by an addi-
tional 50 ml injection of 6 (500 mg/ml) in 5 mM sodium phosphate buffer
(pH 7.4) containing hexadecyltrimethylammonium chloride (1 mM).
Remaining activated sites on the chip surface were blocked with a
35 ml injection of an ethanolamine hydrochloride solution (1 M [pH
8.5]). A second flow cell of the CM5 chip was used as negative control
after activation with EDC and NHS followed by treatment with ethanol-
amine solution as described above. An increase of approximately 300
response units was detected in the flow cell containing 6 when com-
pared to the control cell.
Measurement of FGF-2-Hexasaccharide 6 Interactions
in the Presence of Soluble Competitors
A 30 ml injection of a series of mixtures containing FGF-2 (25 nM) and
competitor (0.5 nM to 500 mM) in HEPES buffer (10 mM HEPES [pH
7.4], 300 mM NaCl, 3 mM EDTA, 0.01% v/v Tween 20) was made at
a flow rate of 10 ml/min. The concentration of NaCl in the HEPES buffer
was increased to 300 mM to eliminate nonspecific background binding
[34]. At the end of the sample injection, the same buffer was flowed
over the sensor surface for 30 s, and then the chip surface was regen-
erated for the next sample by injecting a 50 ml pulse of 4 M NaCl fol-
lowed by a 50 ml pulse of 0.5% sodium dodecyl sulfate (SDS), both
at 50 ml/min. The response was monitored as a function of time (sen-
sorgram). All experiments were carried out at least in duplicate.
ERK1/2 Activation Assay
Rat skeletal muscle myoblasts stably expressing the IIIc variant of
FGFR1 [41] were grown to confluency in Dulbecco’s modified Eagle’s
medium (Sigma, Munich, Germany), supplemented with 10% fetal calf
serum (BioConcept Amimed, Allschwil, Switzerland) and 1% penicillin/
streptomycin, serum starved for 24 hr, and subsequently treated
with different combinations of FGF-2 (5 ng/ml; Roche, Rotkreuz,Chemistry & Biology 14, 87Switzerland) and additives (see below) for 10 min at 37C. FGF-2
was incubated for 1 hr at room temperature in the presence or absence
of different concentrations of heparin (15 U/ml; Sigma), 1, 5, or 6 and
subsequently added to the starved cells. After treatment, cells were
lysed on ice with 200 ml of lysis buffer (20% glycerin, 100 mM Tris/
HCl [pH 8], 3 g/l SDS, 5% b-mercaptoethanol, 2 mM EDTA, 0.5 mM
AEBSF, 1 mM Na2P2O7, 1 mM Na3VO4) per 6 cm plate. Equal amounts
of total protein were analyzed by western blotting using antibodies
against phosphorylated ERK1/2 (P-ERK1/2; Cell Signaling, Danvers,
MA, USA), total ERK1/2 (Cell Signaling), or glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH; HyTest Ltd., Turku, Finland). Detec-
tion of antibody-binding proteins was performed with the alkaline
phosphatase detection system (Promega, Madison, WI, USA).
Supplemental Data
Supplemental Data include 1H-NMR spectra of glycodendrimers,
additional pictures of eight-well arrays, IC50 determination for 5 kDa
heparin, and negative and positive control experiments for the micro-
array and SPR assays and are available at http://www.chembiol.com/
cgi/content/full/14/8/879/DC1/.
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